高血压表观遗传药理学研究进展

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (3): 351-355.

高血压表观遗传药理学研究进展

匡泽民, 黄志军, 阳国平, 袁洪

¹中南大学湘雅三医院心内科
²中南大学湘雅三医院临床药理中心
³中南大学药物临床评价研究中心,长沙 410013,湖南

收稿日期:2012-09-18 修回日期:2012-12-31 出版日期:2013-03-26 发布日期:2013-04-02
通讯作者: 袁洪,通信作者,男,主任医师,教授,博士生导师,研究方向:高血压个体化诊断与治疗。Tel: 0731-88618319 E-mail: yuanhong1975@163.com
作者简介:匡泽民,男,博士研究生,主治医师,研究方向:高血压个体化诊断与治疗。Tel: 15874999711 E-mail: kzmkk@foxmail.com
基金资助:
中南大学中央高校基本科研业务费专项资金资助(2012zzts036);国家重大新药创制专项(2012ZX09303014-001);十二五国家科技支撑计划(SQ2012BAJY3779);973前期研究专项(2011CB512001)

Apparent pharmacogenetics in antihypertensive therapy

KUANG Ze-min, HUANG Zhi-jun, YANG Guo-ping, YUAN Hong

¹Cardiovascular Department, the Third Xiangya Hospital of Central South University
²Center of Clinical Pharmacology, the Third Xiangya Hospital of Central South University
³Drug clinical Evaluation Research center, Central South University, Changsha 410013,Hunan,China

Received:2012-09-18 Revised:2012-12-31 Online:2013-03-26 Published:2013-04-02

摘要/Abstract

摘要： 伴随着遗传药理学的发展,人们逐渐认识到基因多态性不能完全解释降压药物疗效的个体差异。在分子水平上,高血压药物相关代谢酶、受体、转运体都受到基因表达调控的影响,并在降压疗效差异中起着重要的作用。因此,从表观遗传学的角度研究遗传因素与降压药物之间的关系,将有助于更好地解释临床上药物反应产生的个体差异。本文综述总结了DNA甲基化、组蛋白修饰和microRNAs等表观遗传调控方式对高血压相关药物编码基因的影响。

关键词: 表观遗传学, 遗传药理学, DNA甲基化, 组蛋白修饰, microRNAs, 高血压

Abstract: With the development of pharmacogenetics,people gradually realize that gene polymorphism cannot fully explain the antihypertensive drugs curative effect of individual differences. At the molecular level,many antihypertensive drugs related metabolic enzyme,receptors,transporter are subject to the influence of the regulation of gene expression,and play an important role in differences of antihypertensive treatment. Therefore, from the perspective of epigenetics genetic factors and the relationship between the antihypertensive drugs,will help to better explain the clinical drug reaction from the individual differences. This review summarizes the DNA methylation,histone modification and microRNAs,apparent genetic control way for antihypertensive related drugs coding genetic effects.

Key words: Epigenetics, Pharmacogenetics, DNA methylation, Histone Modification, MicroRNAs, Hypertension

中图分类号:

R968

匡泽民, 黄志军, 阳国平, 袁洪. 高血压表观遗传药理学研究进展[J]. 中国临床药理学与治疗学, 2013, 18(3): 351-355.

KUANG Ze-min, HUANG Zhi-jun, YANG Guo-ping, YUAN Hong. Apparent pharmacogenetics in antihypertensive therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 351-355.

参考文献

[1] Glubb DM,Innocenti F. Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters[J]. Wiley Interdiscip Rev Syst Biol Med, 2011, 3(3): 299-313.
[2] Kim GH, Ryan JJ, Marsboom G, et al. Epigenetic mechanisms of pulmonary hypertension[J]. Pulm Circ,2011, 1(3): 347-356.
[3] Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response[J]. Clin Pharmacol Ther, 2012, 92(6): 727-736.
[4] Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease[J]. Circulation,2011,123(19): 2145-2156.
[5] 刘海燕, 袁洪, 黄志军, 等. DNA甲基化与药物效应的表观遗传药理学研究进展[J]. 中国临床药理学, 2012, 28(2): 62-65.
[6] 杜霞, 袁洪, 邢晓为. DNA甲基化与原发性高血压的研究进展[J]. 生物化学与生物物理进展,2010,37 (4): 364-369.
[7] Evison BJ,Bilardi RA,Chiu FC, et al. CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity[J]. Nucleic Acids Res, 2009,37(19):6355-6370.
[8] Gomez A, Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response[J]. Clin Pharmacol Ther,2009,85(4): 426-430.
[9] Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects[J]. Clin Pharmacol Ther,2006,80(6): 646-656.
[10] Baker EK, El-Osta A. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing[J]. Methods Mol Biol,2010, 596: 183-198.
[11] Kim KA, Park PW, Park JY. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects[J]. Br J Clin Pharmacol, 2007, 63(1): 53-58.
[12] Nakano H, Nakamura Y, Soda H, et al. Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells[J]. Cancer, 2008, 112(5): 1122-1130.
[13] 郭军, 蔡军, 李自成. 原发性高血压患者ABCG4基因启动子的甲基化差异分析[J].中国病理生理杂志,2011,27(11): 2067-2071.
[14] Yuan H, Huang Z, Yang G, et al. Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol[J]. J Int Med Res, 2008, 36(6): 1354-1362.
[15] Jiang Q, Yuan H, Xing X, et al. Methylation of adrenergic beta1 receptor is a potential epigenetic mechanism controlling antihypertensive response to metoprolol[J]. Indian J Biochem Biophys, 2011,48(5): 301-307.
[16] Yuan H, Huang ZJ, Xing XW, et al. Inhibitors of DNA methyltransferase and histone deacetylase regulate the expression of β1-adrenoceptor gene in myocardial cells[J]. Cell Biol Int, 2008, 32(3): S7-S8.
[17] Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma[J]. Nature,2011,476(7360): 298-303.
[18] Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma[J]. Nature,2011,476(7360): 298-303.
[19] Chen B, Li H, Zeng X, et al. Roles of microRNA on cancer cell metabolism[J].J Transl Med, 2012, 10(1): 228.
[20] Mateo LI, der Harst PV, de Boer RA. Pharmacoepigenetics in heart failure[J].Curr Heart Fail Rep,2010,7(2): 83-90.
[21] Esteller M. Epigenetics in cancer[J].N Engl J Med,2008,358(11): 1148-1159.
[22] Mano H. Epigenetic abnormalities in cardiac hypertrophy and heart failure[J]. Environ Health Prev Med, 2008, 13(1): 25-29.
[23] Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation[J]. BMC Genomics, 2006, 7: 181.
[24] Li Y, Cui Y, Hart SN, et al. Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation[J].Mol Pharmacol, 2009, 75(5): 1171-1179.
[25] Portela A, Esteller M. Epigenetic modifications and human disease[J].Nat Biotechnol,2010, 28(10): 1057-1068.
[26] Pollard SM, Stricker SH, Beck S. A shore sign of reprogramming[J]. Cell Stem Cell, 2009,5(6): 571-572.
[27] Schroen B, Heymans S. MicroRNAs and beyond: the heart reveals its treasures[J]. Hypertension,2009, 54(6): 1189-1194.
[28] Ronneberg JA, Tost J, Solvang HK, et al. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas[J].Cancer Res,2008, 68(14): 5562-5571.
[29] Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells[J].Biochem Pharmacol, 2008, 76(5): 582-588.
[30] Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin[J].Mol Cancer Ther,2008, 7(7): 2152-2159.
[31] Dorn GW 2nd. MicroRNAs in cardiac disease[J]. Transl Res,2011, 157(4): 226-235.
[32] Han M, Toli J, Abdellatif M. MicroRNAs in the cardiovascular system[J].Curr Opin Cardiol,2011,26(3): 181-189.
[33] 杨杰, 谭洁, 邹建军, 等. P450酶和转运体的DNA甲基化调控:提示药物反应的个体差异[J].中国临床药理学与治疗学, 2010,15(11): 1294-1299.